Cargando…
Immunoregulatory Biomarkers of the Remission Phase in Type 1 Diabetes: miR-30d-5p Modulates PD-1 Expression and Regulatory T Cell Expansion
The partial remission (PR) phase of type 1 diabetes (T1D) is an underexplored period characterized by endogenous insulin production and downmodulated autoimmunity. To comprehend the mechanisms behind this transitory phase and develop precision medicine strategies, biomarker discovery and patient str...
Autores principales: | Gomez-Muñoz, Laia, Perna-Barrull, David, Murillo, Marta, Armengol, Maria Pilar, Alcalde, Marta, Catala, Marti, Rodriguez-Fernandez, Silvia, Sunye, Sergi, Valls, Aina, Perez, Jacobo, Corripio, Raquel, Vives-Pi, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037622/ https://www.ncbi.nlm.nih.gov/pubmed/36960962 http://dx.doi.org/10.3390/ncrna9020017 |
Ejemplares similares
-
Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes
por: Gomez-Muñoz, Laia, et al.
Publicado: (2022) -
NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes
por: Gomez-Muñoz, Laia, et al.
Publicado: (2021) -
Prenatal Betamethasone Exposure and its Impact on Pediatric Type 1 Diabetes Mellitus: A Preliminary Study in a Spanish Cohort
por: Perna-Barrull, David, et al.
Publicado: (2022) -
Immune System Remodelling by Prenatal Betamethasone: Effects on β-Cells and Type 1 Diabetes
por: Perna-Barrull, David, et al.
Publicado: (2020) -
Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential
por: Rodriguez-Fernandez, Silvia, et al.
Publicado: (2019)